These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 39284337)

  • 21. VHL mutation analysis in patients with isolated central nervous system haemangioblastoma.
    Woodward ER; Wall K; Forsyth J; Macdonald F; Maher ER
    Brain; 2007 Mar; 130(Pt 3):836-42. PubMed ID: 17264095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
    Jonasch E; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Dror Michaelson M; Appleman LJ; Roy A; Perini RF; Liu Y; Choueiri TK
    Eur J Cancer; 2024 Jan; 196():113434. PubMed ID: 38008031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
    Choueiri TK; Powles T; Peltola K; de Velasco G; Burotto M; Suarez C; Ghatalia P; Iacovelli R; Lam ET; Verzoni E; Gümüş M; Stadler WM; Kollmannsberger C; Melichar B; Venugopal B; Gross-Goupil M; Poprach A; De Santis M; Schutz FA; Park SH; Nosov DA; Porta C; Lee JL; Garcia-Del-Muro X; Biscaldi E; Manneh Kopp R; Oya M; He L; Wang A; Perini RF; Vickery D; Albiges L; Rini B;
    N Engl J Med; 2024 Aug; 391(8):710-721. PubMed ID: 39167807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.
    Gläsker S; Bender BU; Apel TW; van Velthoven V; Mulligan LM; Zentner J; Neumann HP
    J Neurol Neurosurg Psychiatry; 2001 May; 70(5):644-8. PubMed ID: 11309459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor.
    Pelle E; Al-Toubah T; Morse B; Strosberg J
    J Natl Compr Canc Netw; 2022 Dec; 20(12):1285-1287. PubMed ID: 36509068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype-phenotype correlation in von Hippel-Lindau disease.
    Reich M; Jaegle S; Neumann-Haefelin E; Klingler JH; Evers C; Daniel M; Bucher F; Ludwig F; Nuessle S; Kopp J; Boehringer D; Reinhard T; Lagrèze WA; Lange C; Agostini H; Lang SJ
    Acta Ophthalmol; 2021 Dec; 99(8):e1492-e1500. PubMed ID: 33720516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First clinical experience with belzutifan in von Hippel-Lindau disease associated CNS hemangioblastoma.
    Dhawan A; Peereboom DM; Stevens GH
    CNS Oncol; 2022 Jul; 11(3):CNS91. PubMed ID: 35819008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-Response Analyses for Belzutifan to Inform Dosing Considerations and Labeling.
    Marathe DD; Jauslin PM; Jan Kleijn H; De Miranda Silva C; Chain A; Abraham AK; Kauh EA; Liu Y; Perini RF; Alwis DP; Jain L
    J Clin Pharmacol; 2024 Oct; 64(10):1246-1258. PubMed ID: 38752556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
    Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
    Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TWO CASES OF VON HIPPEL-LINDAU SYNDROME-ASSOCIATED RETINAL HEMANGIOBLASTOMA TREATED WITH BELZUTIFAN.
    Grimes JM; Gershkovich A; Bogomolny D; Marr BP
    Retin Cases Brief Rep; 2024 May; 18(3):319-322. PubMed ID: 36730578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
    Choueiri TK; Bauer TM; Papadopoulos KP; Plimack ER; Merchan JR; McDermott DF; Michaelson MD; Appleman LJ; Thamake S; Perini RF; Zojwalla NJ; Jonasch E
    Nat Med; 2021 May; 27(5):802-805. PubMed ID: 33888901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
    Choi WW; Boland JL; Kalola A; Lin J
    Curr Oncol Rep; 2023 Feb; 25(2):123-129. PubMed ID: 36630072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
    Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
    J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system].
    Zhou J; Li NY; Zhou XJ; Zhou HB; Wu B; Jiang SJ; Ma HH; Zhang RS
    Zhonghua Bing Li Xue Za Zhi; 2010 Mar; 39(3):145-50. PubMed ID: 20450758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease.
    Knoblauch AL; Blaß BI; Steiert C; Neidert N; Puzik A; Neumann-Haefelin E; Ganner A; Kotsis F; Schäfer T; Neumann HPH; Elsheikh S; Beck J; Klingler JH
    J Neurooncol; 2024 Jul; 168(3):537-545. PubMed ID: 38647646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. von Hippel-Lindau disease: a clinical and scientific review.
    Maher ER; Neumann HP; Richard S
    Eur J Hum Genet; 2011 Jun; 19(6):617-23. PubMed ID: 21386872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 10-year retrospective study of hemangioblastomas of the central nervous system with reference to von Hippel-Lindau (VHL) disease.
    Padhi S; Sarangi R; Challa S; Bussary P; Panigrahi MK; Purohit AK
    J Clin Neurosci; 2011 Jul; 18(7):939-44. PubMed ID: 21570297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
    Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
    Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.